illustration of a Chinese expert working in a medicine lab

By Doug Young & Rene Vanguestaine

After several years of unbridled enthusiasm, investors have sharply pulled back their support for Chinese healthcare startups. Why the sudden cold feet toward this group? And a decade after acquiring U.S. pork giant Smithfield, China’s WH Group is eyeing a New York listing for the company. Could this be prelude to a sale of this pork barrel investment?

About China Inc

China Inc by Bamboo Works discusses the latest developments on Chinese companies listed in Hong Kong and the United States to drive informed decision-making for investors and others interested in this dynamic group of companies.

Subscribe to China Inc on your favorite app:

Apple Podcasts Spotify

Recent Articles

cars are a consumer product

Sales growth lifts JNBY’s annual profit over 10%

Apparel brand JNBY Design Ltd. (3306.HK) on Wednesday reported its revenue rose 9% year-over-year to 6.05 billion yuan ($901 million) in its fiscal year through June 30, as its profit rose 11.7% to 997…
Salubris refiles for Hong Kong IPO

Salubris refiles for Hong Kong IPO as generics lose steam

The producer of cardiovascular drugs is accelerating its shift towards innovative pharmaceuticals, under pressure from price cuts and expiring patents Key Takeaways: Salubris built its early success on generics, but…